Eczema is one of the most common inflammatory skin diseases that accounts for up to 40% of all dermatological diseases. According to WHO, about 3% of the adult population in the world is affected by dermatosis, and this indicator has been constantly growing. In this regard, the problem of pathogenetic treatment of eczema not only remains relevant but also gains more scientific, practical and social importance. Aim. The aim of the stusy was to investigate the efficacy of Cytoflavin as a part of standard treatment for eczema. Material and methods. A single-blind, randomized comparative study was conducted in parallel groups of 70 eczema patients at the age of 17 to 77 years who were in the relapse phase of the skin process. Patients of the 1st group received standard therapy. Patients of the 2nd group received a multicomponent drug, Cytoflavin (POLYSAN, Russia), 2 tablets 2 times a day, 30 min before eating, washing down it with 100 mL of water (evening drug administration was before 6 p.m.) in association with standard therapy. The duration of treatment was 25 days. International standards, clinical observation, a WAM test, and the evaluation dermatology life quality index (DLQI) were used. To assess the severity of homeostasis disorders, indicators characterizing endotoxicosis and processes of lipid peroxidation and antioxidant defense were studied. Several indicators of immunity and the cytokine profile were investigated. As controls, 16 clinically healthy donors (mean age was 33.5±3.27 years) were examined. Results of the study were processed using variation statistics of the biomedical profile. Results. According to the obtained results, patients with eczema developed the endogenous intoxication syndrome associated with depression of antioxidant protection; changes in the immune homeostasis and psychoemotional state were found. These findings required targeted metabolic correction. The use of Cytoflavin in combined treatment of eczema promoted more rapid regression of the pathological skin process; clinical recovery occurred in 40.0% of cases, the dermatological index of the symptoms scale was decreased by 83.0%, and the EASI index was decreased by 90.9%. The use of Cytoflavin in combined therapy of eczema had a positive effect on the emotional state of patients and improved the quality of life of patients with dermatoses. Changes in cytokine secretion upon eczema are controlled by the functional properties of pro-inflammatory cytokines: IL-6, IL-8, and TNF-α. Cytoflavin in association with combined therapy for dermatosis promoted a reduction in the phagocytosis activity by 14.4%, TNF-α in 5.3 times upon reducing the IL-8 level in 6.3 times. Cytoflavin-based combined therapy improved parameters of lipid peroxidation (reduction in diene conjugates and diene ketones in 1.2 times) and endotoxicosis (decrease in the plasma Fe-MDA concentrations by 49.3%, circulating immune complexes (CIC) of small diameter by 16.5%, and MMM254 by 9.6%), with the catalase activity being increased in plasma and erythrocytes. Conclusions. The use of Cytoflavin in association with standard treatment for eczema provided positive clinical and laboratory results confirmed by the correlation data that makes it possible to use this therapy for dermatosis patients in practice.